[{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Nichi-Iko Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Limaprost Alfadex","moa":"PGE2","graph1":"Neurology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals for Limaprost Alfadex

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Nichi-Iko will convert the formulation of “Limaprost Alfadex tablets 5 µg to a formulation which has been improved for moisture resistance stability following the technology transfer.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 05, 2020

                          Lead Product(s) : Limaprost Alfadex

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Nichi-Iko Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank